MedBiome partners its advanced microbiome technology, called RapidAIM, for drug discovery, compound screening and development needs of pharmaceutical and biotech companies.

• focuses on screening compounds against individual microbiomes (human and animals)
• develops compound libraries that can reach the gut microbiome
• provides industry-leading functional metaproteomics, metagenomics and metabolomics approaches
• provides leading bioinformatics and software tools to assess the effects of drugs on the microbiome